Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-1.21 |
N/A |
N/A |
N/A |
2024-02-22 |
2023-12 |
-1.13 |
-1.28 |
-0.15 |
-13.27% |
2023-10-26 |
2023-09 |
-1.06 |
-1.1 |
-0.04 |
-3.77% |
2023-08-03 |
2023-06 |
-1.1 |
-1.78 |
-0.68 |
-61.82% |
2023-05-04 |
2023-03 |
-1.08 |
-1.17 |
-0.09 |
-8.33% |
2023-02-23 |
2022-12 |
-1 |
-1.2 |
-0.2 |
-20.00% |
Date |
Firm |
Action |
From |
To |
2023-09-20 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-09-18 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-09-06 |
Evercore ISI Group |
Upgrade |
Outperform |
Outperform |
2023-09-05 |
B of A Securities |
Upgrade |
Buy |
Buy |
2023-09-05 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-09-04 |
Guggenheim |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-11 |
ADSETT ROGER |
Chief Operating Officer |
148.56K |
Sale |
2024-01-08 |
BONSTEIN SARA M |
Chief Financial Officer |
114.05K |
Sale |
2024-01-11 |
FLAMMER MARTINA |
Officer |
106.90K |
Sale |
2024-02-27 |
LEWIS WILLIAM H |
Chief Executive Officer |
0.00 |
Conversion of Exercise of derivative security |
2023-05-10 |
MCGIRR DAVID W J |
Director |
85.75K |
Stock Award(Grant) |
2024-01-08 |
SCHAEFFER ORLOV S NICOLE |
Officer |
101.98K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
13.32M |
281.06M |
9.26% |
2023-06-29 |
Blackrock Inc. |
10.26M |
216.45M |
7.13% |
2023-06-29 |
Price (T.Rowe) Associates Inc |
10.17M |
214.64M |
7.07% |
2023-06-29 |
T. Rowe Price Investment Management, Inc. |
8.30M |
175.22M |
5.77% |
2023-06-29 |
Deep Track Capital, Lp |
6.50M |
137.15M |
4.52% |
2023-06-29 |
State Street Corporation |
6.02M |
127.03M |
4.19% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Price (T.Rowe) New Horizons Fund |
4.38M |
92.40M |
3.05% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
4.28M |
90.34M |
2.98% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
3.52M |
74.32M |
2.45% |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
3.13M |
68.55M |
2.18% |
2023-08-30 |
iShares Russell 2000 ETF |
3.00M |
65.66M |
2.09% |
2023-05-30 |
Delaware Group Equity Fds V-Small Cap Core Fund |
2.55M |
48.51M |
1.77% |
Split |
Date |
0.1 : 1 |
2011-03-03 |
0.25 : 1 |
2000-07-31 |